Tier B · Substantial human research
LL-37
An endogenous antimicrobial peptide with genuine randomized human wound-healing research.
Why researchers care
Potential human relevance
- Topical LL-37 has been studied in hard-to-heal venous leg ulcers
- Early randomized trials reported accelerated wound healing at selected concentrations
- Combines antimicrobial and host-defense biology
What the human evidence says
Evidence, not extrapolation
LL-37 has meaningful human wound research, but results are formulation- and dose-dependent. It is not a general-purpose systemic immune peptide with established benefits.
How to think about it
The Yooper Peptides take
LL-37 shows why exact context matters: a topical peptide can have promising local wound effects without proving broad systemic use.
Primary / authoritative reading